Please login to the form below
AB Science
This page shows the latest AB Science news and features for those working in and with pharma, biotech and healthcare.
CHMP backs first-line use for AZ’s Tagrisso in lung cancer
The three drugs in question are Portola’s anticagulant Dexxience (betrixaban), Radius’ osteoporosis candidate Eladynos (abaloparatide) and AB Science’s Alsitek (masitinib), filed for neurodegenerative disease amyotrophic lateral sclerosis (ALS)
Latest news
-
FDA clears new ALS drug Radicava ahead of schedule
In March, French biotech AB Science said a pivotal trial of its lead drug masitinib for ALS hit its objectives of reducing declines in functioning when added to Riluzole therapy.
-
AB Science claims first with motor neurone disease therapy
ALS patients on masitnib lived longer without their disease progressing. French biotech AB Science is celebrating after a pivotal trial of its lead drug masitinib for motor neurone disease hit its ... This is very good news for the patients," said AB
-
Dementia research alliance to fast-track new Alzheimer's drugs
Industry pipelines of potential Alzheimer's treatments have taken multiple hits in recent years, although just last week AB Science revealed it was still on track to release phase III clinical
-
AB Science on track for phase III data in Alzheimer's this year
Trial of masitinib has passed a futility test. French biotech company AB Science has announced some positive news in its Alzheimer's programme as its phase III trial has been successful ... AB Science seems to be taking a scattergun approach to
-
CHMP turns down Avastin for brain cancer
At its meeting last week the CHMP also confirmed its negative opinion - after a re-examination - on AB Science's Masiviera (masitinib) for certain types of advanced pancreatic cancer and Novartis'
More from news
Approximately 3 fully matching, plus 5 partially matching documents found.
Subscribe to our email news alerts
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- MHRA to introduce new UK clinical trials framework
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Pfizer and Astellas’ Xtandi shows promise in phase 3 prostate cancer study
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- VR/AR Applications for Training and Healthcare
PMHub
Six Degrees Medical Consulting
For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
